All In Biotech

Drug Trial Radar · NCT02221102

Edoxaban for TIA and Acute Minor Stroke

Treatment of Edoxaban Versus Aspirin for Non-disabling Cerebrovascular Events: Rationale, Objectives, and Design

Last checked: Nov 20, 2026Latest source record: Aug 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 3,700 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

3,700

Planned (sponsor's estimate)

Start

Dec 2013

Primary completion

Jun 2015

Study completion Jun 2016

Sponsor

Lead sponsor
Xijing HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 20, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Transient ischemic attack (TIA) or minor ischemic stroke has a high risk of early recurrent stroke. As the golden standard, aspirin effect modestly on acute ischemic stroke, and slightly increase the risk of intracerebral hemorrhage. Recently, edoxaban, a new oral anticoagulant, is proved to be as effective as traditional anticoagulants, while carrying significantly less risk of intracranial hemorrhage. This trial is a randomized, double-blind, multicenter, controlled clinical trial in China. The investigators will assess the hypothesis that a 30-days edoxaban regimen is superior to aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event.

Conditions

  • Ischemia
  • Stroke
  • Cerebral Infarction

Interventions

  • AspirinDrug

    non-steroidal anti-inflammatory drugs

  • edoxabanDrug

    orally active direct factor Xa inhibitor

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. percentage of patients with new stroke (ischemic or hemorrhage)Time frame: 90 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xijing Hospital

    Xi'an, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.